echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The $12.5 billion acquisition of Qiagen by "Pharmaceutical Headliner" Seymru Hassell has failed.

    The $12.5 billion acquisition of Qiagen by "Pharmaceutical Headliner" Seymru Hassell has failed.

    • Last Update: 2020-09-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    (2020/08/14) PD-1 track "killing" fierce Hengrui, Xinda and so on in the adaptive "battleground" who has the upper hand; When the new crown vaccine meets the micro-dealer; (Click on the title to get the original article) 1st Time of Medicine Thermo Feisser's $12.5 billion acquisition of Qiagen has come to an end.
    the acquisition agreement between the two companies has been declared invalid in accordance with the terms and conditions, as the minimum acceptance threshold for the acquisition has not been met.
    said the $12.5bn offer was the "best and final offer" but did not meet Qiagen's investor expectations.
    headlines: The company's share price has now surpassed Thermo's initial offer.
    "E drug manager" PD-1 track "killing" fierce Hengrui, Xinda and so on in the adaptive "battleground" who has the upper hand on the 12th, Xinda Bio announced that the company and Lilly jointly developed the innovative PD-1 The application for a new adaptive drug for the first-line treatment of squamous non-small cell lung cancer NSCLC by inhibitor Daboshu (Syndicly monoantigen injection) and platinum chemotherapy was formally accepted by the State Drug Administration.
    Previously, the National Drug Administration has also officially accepted the sDNA of Dabershu (Syndili monoantigen injection) combined libita (injected with pyridoxine di sodium) and platinum for non-scaly NSCLC first-line treatment.
    headlines: PD-1 hot layout.
    new Kangjie listed in September, 498 yuan a! When the new crown vaccine meets the micro-business new crown vaccine has not yet been listed, but there are micro-business has been sold? According to the Shanghai Network rumors, recently, the circle of friends in the micro-business sold a new crown vaccine, there is more than one! The first brush screen of the "new crown vaccine" text reads: "need the new crown vaccine contact me, can do export, low production needs to queue, September 2 officially listed", pictured is an orange box.
    : Epidemic prevention and resistance is about human life.
    The East Sun Medicine, Koren, Qilu... Take 38 first imitation 18 billion market changes! Recently, Jiangxi Shanxiang Pharmaceutical Co., D.C., toluene sulfonate soraphine tablets were approved for the market, for the domestic first imitation.
    meters of intranet data show that so far, 2020 has 38 first imitation approved for listing, the original research products in 2019 China's public medical institutions terminal total sales of more than 18 billion; Including subsidiaries) with 5 first imitation leader, Grigg Ingham, AstraZeneta has 5 varieties, 3 varieties of the birth of the first imitation, 14 heavyweight first imitation is expected to be approved by the end of 2020, from Zhengda Tianqing, Hengrui, Yangzijiang and other enterprises.
    : The domestic blank market is filled.
    what kind of Donaveni is before it is listed? Not long ago, the industry's attention to the 2020 "China Clinical Oncology Society (CSCO) primary liver cancer diagnosis and treatment guide" officially released, in the process of learning the new guidelines found that the domestic independent development of the drug toluene sulphate donaphine was included in the guide, and recommended for I-level experts! It is worth noting that the variety has not yet been approved for listing! Headline bacteria: the company's development positioning has been very clear.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.